Compare INFU & BDTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | INFU | BDTX |
|---|---|---|
| Founded | 2005 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 182.4M | 116.8M |
| IPO Year | 2005 | 2020 |
| Metric | INFU | BDTX |
|---|---|---|
| Price | $9.60 | $2.17 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 6 |
| Target Price | ★ $15.00 | $10.20 |
| AVG Volume (30 Days) | 112.2K | ★ 578.5K |
| Earning Date | 05-07-2026 | 03-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 181.82 | 130.71 |
| EPS | 0.31 | ★ 0.39 |
| Revenue | ★ $143,436,000.00 | N/A |
| Revenue This Year | $2.89 | N/A |
| Revenue Next Year | $7.66 | N/A |
| P/E Ratio | $30.97 | ★ $5.56 |
| Revenue Growth | ★ 6.36 | N/A |
| 52 Week Low | $4.61 | $1.20 |
| 52 Week High | $11.04 | $4.94 |
| Indicator | INFU | BDTX |
|---|---|---|
| Relative Strength Index (RSI) | 62.04 | 43.39 |
| Support Level | $9.73 | $1.93 |
| Resistance Level | $9.83 | $2.86 |
| Average True Range (ATR) | 0.47 | 0.14 |
| MACD | 0.04 | -0.00 |
| Stochastic Oscillator | 93.89 | 38.02 |
InfuSystems Holdings Inc is a health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers. INFU services are provided under a two-reportable segment. The first is Patient Services, providing the last-mile solution for clinic-to-home healthcare where the continuing treatment involves complex durable medical equipment and services. The Patient segment is comprised of Oncology, Pain Management and Wound Therapy businesses. The second, Device Solutions, supports the Patient Services platform and leverages service orientation to win incremental business from its direct payer clients. The Device segment is comprised of direct payer rentals, pump and consumable sales, and biomedical services and repair. Majority from Patient.
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. It is engaged in the discovery and development of small molecule, tumor-agnostic therapies. The company has one pipeline technology platform, namely Mutation-Allostery-Pharmacology, which is targeting mutations in cancer. Its drugs under the pipeline are BDTX-4933 and BDTX-1535.